ArticleOpen medicine (Warsaw, Poland)2025
Molecular genotyping of multi-system rare blood types in foreign blood donors based on DNA sequencing and its clinical significance.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To establish a multi-level blood type identification system, comprehensively analyze the distribution characteristics and genetic polymorphisms of multi-system rare blood types in foreign blood donors, explore the application value of DNA sequencing technology in rare blood type screening, and evaluate its clinical significance in complex transfusion patients. Methods: Blood samples from 277 foreign blood donors who participated in voluntary blood donation in Yiwu City were prospectively collected from June 2021 to March 2023. Serological typing of 24 antigens from 11 red blood cell blood group systems (ABO, Rh, Duffy, MNS, Kidd, Kell, Lutheran, P1PK, Lewis, H, and Diego) was performed using microcolumn agglutination and tube methods. First-generation sequencing technology was used to perform whole-exome sequencing of Duffy, Kell, Ss/GYPB, and Diego genes on screened rare phenotype samples to analyze genetic polymorphism characteristics. Key mutation sites were verified using multiplex PCR-sequencing. A rare blood type DNA database was established and compared with the international blood group gene database (BGMUT). Confirmed rare blood type units were preserved through programmed freezing, and their clinical application effects were tracked and analyzed. Results: The 277 foreign blood donors were primarily from the Middle East and South Asia (71.8%), with major source countries including Syria (56 cases, 20.22%), Yemen (49 cases, 17.69%), Pakistan (24 cases, 8.66%), Iraq (20 cases, 7.22%), India (15 cases, 5.42%), Iran (14 cases, 5.05%), Mali (11 cases, 3.97%), and Jordan (10 cases, 3.61%). In blood type distribution, Fya antigen expression was highest among Indian (100%) and Pakistani (87.50%) donors; 63 cases of Fy(a-b-) were found, most commonly in donors from Mali and Yemen. S antigen expression was highest in donors from Syria (60.71%), India (60.00%), and Pakistan (58.33%); 47 cases of S+s- were detected. Additionally, 12 cases of Lua+ were found, distributed among Syria (3 cases), Iraq (2 cases), Yemen (2 cases), Jordan (2 cases), etc.; 5 cases of Kpa+ were from Yemen (2 cases), Pakistan, Iraq, and Jordan (1 case each). DNA sequencing revealed that GATA-1 promoter region mutation (c.-67T>C) in the Duffy gene was the primary molecular basis for the Fy(a-b-) phenotype, accounting for 96.8% (61/63). Multivariate analysis demonstrated significant clustering of blood group phenotypes by geographical regions ( Conclusion: Foreign blood donors exhibit significant regional and ethnic polymorphic characteristics in red cell blood types. A multi-level blood type identification system based on DNA sequencing can improve the accuracy and efficiency of rare blood type screening. Establishing a standardized genetic typing strategy for rare blood types in foreign donors has important clinical translation value for constructing diverse rare blood type resources and addressing complex transfusion needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.